ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
| 対象疾患 | Ovarian Cancer |
|---|---|
| 相 | 第1/2相 |
| スポンサー | Michael McHale |
| ステータス | 早期終了 |
| 参加者数 | 8 名 |
| 介入（薬剤） | VS-6063, Paclitaxel, Carboplatin |
| 開始日 | 2018年2月6日 |
| 完了日 | 2023年7月30日 |
| 結果公開日 | 2026年7月31日 |
概要
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.
Dose-Limiting Toxicity
| Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | 1 Participants |
|---|---|
| Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | 1 Participants |
Objective Response Rate (ORR)
| Defactinib (VS-6063) + Carboplatin/Paclitaxel | 0 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)